Sophie C. Doettl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sophie C. Doettl has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Malandrino
Department for Orthopaedics and Traumatology, Johannes Kepler University Linz, Kepler University Hospital, Altenberger Strasse 69, 4040 Linz and Krankenhausstrasse 5, 4020, Linz, Austria
2 shared publications Cornelia Bergmayr
2 shared publications- Cornelia Schmutz
Department of Food Chemistry and Toxicology, Faculty of Chemistry, University of Vienna, Währingerstraße 38-40, 1090 Vienna, Austria
2 shared publications - Eleni Priglinger
Department for Orthopaedics and Traumatology, Johannes Kepler University Linz, Kepler University Hospital, Altenberger Strasse 69, 4040 Linz and Krankenhausstrasse 5, 4020, Linz, Austria
2 shared publications - Alexa von Mueffling
Department of Cardiac Surgery, Boston Children’s Hospital, Boston, MA 02115, USA
1 shared publication - Andrei-Antonio M. Caracioni
Department of Cardiac Surgery, Boston Children’s Hospital, Boston, MA 02115, USA
1 shared publication
Latest Publications
- Open Access
- 13 November 2026
- Published by Elsevier in Bioprinting
- Vol. 60
Integration of in-line light-mediated cell activation in extrusion-based bioprinting: A new biofabrication strategy for bone tissue engineering
- 13 November 2026
- Published by Elsevier in Bioprinting
- Vol. 60
Open AccessIntegration of in-line light-mediated cell activation in extrusion-based bioprinting: A new biofabrication strategy for bone tissue engineering
- Open Access
Integration of In-Line Light-Mediated Cell Activation in Extrusion-Based Bioprinting: A New Biofabrication Strategy for Bone Tissue Engineering
Controlled activation of cells through photobiomodulation can influence osteogenic outcomes. However, factors such as skin penetration depth limit its clinical relevance. In this study, we present a workflow integrating broadband light stimulation directly into the bioprinting process by equipping a custom, low-cost extrusion bioprinter with a self-made, high-voltage spark-gap stimulation unit, enabling in-line stimulation of cells embedded in hydrogel. Optimal duration of broadband light exposure was screened with SaOS-2 cells in 2D for 5, 10, or 15 min, and cultured under osteogenic and control conditions. In 3D, SaOS-2 or adipose-derived stromal cells (ASCs) were bioprinted in an alginate-gelatin bioink under 10 minutes of pulsatile light stimulation. Cellular responses were assessed after 21 days by cell yield, viability, metabolic activity, apoptosis, DNA damage and osteogenic differentiation through immunofluorescence, histology and qPCR. Additionally, vascularisation capacity was assessed in light-stimulated HUVEC/ASC co-cultures within bioprinted constructs. In 2D, light stimulation did not negatively affect cell yield, viability, metabolic activity, cytotoxicity and DNA damage across all exposure times. 3D cultures showed a 2.7-fold and 2.4-fold increase in calcium and hydroxyapatite, respectively, elevated osteocalcin/collagen type I protein expression and gene expression of ALPL, BGLAP, SPP-1, COL1A1, COL10A1 and no increase in DNA damage after 21 days. In the HUVEC/ASC co-culture, light stimulation promoted endothelial elongation (1.25-fold), network formation (2-fold) and perivascular ASC organisation. This work establishes a proof-of-concept methodology for in-line, broadband light cell activation during bioprinting as a strategy to enhance osteogenic differentiation and vascularisation potential. Abstract Figure:
Open AccessIntegration of In-Line Light-Mediated Cell Activation in Extrusion-Based Bioprinting: A New Biofabrication Strategy for Bone Tissue Engineering
Controlled activation of cells through photobiomodulation can influence osteogenic outcomes. However, factors such as skin penetration depth limit its clinical relevance. In this study, we present a workflow integrating broadband light stimulation directly into the bioprinting process by equipping a custom, low-cost extrusion bioprinter with a self-made, high-voltage spark-gap stimulation unit, enabling in-line stimulation of cells embedded in hydrogel. Optimal duration of broadband light exposure was screened with SaOS-2 cells in 2D for 5, 10, or 15 min, and cultured under osteogenic and control conditions. In 3D, SaOS-2 or adipose-derived stromal cells (ASCs) were bioprinted in an alginate-gelatin bioink under 10 minutes of pulsatile light stimulation. Cellular responses were assessed after 21 days by cell yield, viability, metabolic activity, apoptosis, DNA damage and osteogenic differentiation through immunofluorescence, histology and qPCR. Additionally, vascularisation capacity was assessed in light-stimulated HUVEC/ASC co-cultures within bioprinted constructs. In 2D, light stimulation did not negatively affect cell yield, viability, metabolic activity, cytotoxicity and DNA damage across all exposure times. 3D cultures showed a 2.7-fold and 2.4-fold increase in calcium and hydroxyapatite, respectively, elevated osteocalcin/collagen type I protein expression and gene expression of ALPL, BGLAP, SPP-1, COL1A1, COL10A1 and no increase in DNA damage after 21 days. In the HUVEC/ASC co-culture, light stimulation promoted endothelial elongation (1.25-fold), network formation (2-fold) and perivascular ASC organisation. This work establishes a proof-of-concept methodology for in-line, broadband light cell activation during bioprinting as a strategy to enhance osteogenic differentiation and vascularisation potential. Abstract Figure:
- Open Access
Imatinib Mesylate and Sirolimus Inhibit Vascular Fibroproliferative Remodeling in Pulmonary Vein Stenosis
Background: Pulmonary vein stenosis (PVS) is a progressive disease characterized by neointimal hyperplasia with poor outcomes. Clinical observations show that adjunctive therapy with imatinib mesylate and sirolimus is associated with improved survival and reduced rates of reintervention. In this study, we aimed to investigate the cellular mechanisms underlying PVS development and progression and to elucidate how these targeted therapies modulate these processes. Methods: We retrospectively analyzed cardiac catheterization and computed tomography, and lung scan data from three patients with PVS to estimate wall shear stress (WSS) at multiple time points. Tissue specimens resected during anatomical repair surgery were analyzed for tissue composition and fibrosis using hematoxylin and eosin staining, Masson’s trichrome staining, and flow cytometric analysis of endothelial cell (ECs) and fibroblast markers to determine endothelial-to-mesenchymal transition (EndMT). The safety and efficacy of imatinib mesylate and sirolimus were evaluated in healthy and PVS-derived ECs using cellular viability and proliferation assays, and by assessing fibrotic marker expression indicative of EndMT. Results: Patients exhibited severely elevated WSS estimates at multiple time points throughout disease progression. Disproportionate fibrotic remodeling driven by ECs transitioning into mesenchymal cells through EndMT was the cellular substrate of resected tissue in PVS. Targeted therapy with clinically relevant concentrations of imatinib mesylate and sirolimus was safe and significantly inhibited fibroproliferation and EndMT. At follow-up, all patients were alive and free of surgical and stent-based reintervention after anatomic repair surgery and adjunctive imatinib mesylate and sirolimus therapy. Conclusions: Fibroproliferative ECs undergoing EndMT are likely the cellular substrate underlying PVS development and progression. A multimodal approach consisting of anatomically focused surgical repair with adjunctive imatinib mesylate and sirolimus therapy may attenuate fibroproliferative remodeling.
Open AccessImatinib Mesylate and Sirolimus Inhibit Vascular Fibroproliferative Remodeling in Pulmonary Vein Stenosis
Background: Pulmonary vein stenosis (PVS) is a progressive disease characterized by neointimal hyperplasia with poor outcomes. Clinical observations show that adjunctive therapy with imatinib mesylate and sirolimus is associated with improved survival and reduced rates of reintervention. In this study, we aimed to investigate the cellular mechanisms underlying PVS development and progression and to elucidate how these targeted therapies modulate these processes. Methods: We retrospectively analyzed cardiac catheterization and computed tomography, and lung scan data from three patients with PVS to estimate wall shear stress (WSS) at multiple time points. Tissue specimens resected during anatomical repair surgery were analyzed for tissue composition and fibrosis using hematoxylin and eosin staining, Masson’s trichrome staining, and flow cytometric analysis of endothelial cell (ECs) and fibroblast markers to determine endothelial-to-mesenchymal transition (EndMT). The safety and efficacy of imatinib mesylate and sirolimus were evaluated in healthy and PVS-derived ECs using cellular viability and proliferation assays, and by assessing fibrotic marker expression indicative of EndMT. Results: Patients exhibited severely elevated WSS estimates at multiple time points throughout disease progression. Disproportionate fibrotic remodeling driven by ECs transitioning into mesenchymal cells through EndMT was the cellular substrate of resected tissue in PVS. Targeted therapy with clinically relevant concentrations of imatinib mesylate and sirolimus was safe and significantly inhibited fibroproliferation and EndMT. At follow-up, all patients were alive and free of surgical and stent-based reintervention after anatomic repair surgery and adjunctive imatinib mesylate and sirolimus therapy. Conclusions: Fibroproliferative ECs undergoing EndMT are likely the cellular substrate underlying PVS development and progression. A multimodal approach consisting of anatomically focused surgical repair with adjunctive imatinib mesylate and sirolimus therapy may attenuate fibroproliferative remodeling.